After completing the 3-month active cycle, we offer an optional Optimization Panel for patients who want a full picture of how their body responded
For anabolic agents (testosterone) and peptide hormones (hGH) , a request for review and approval must be submitted to The National Center for Drug Free Sport (NCDFS) through the Director of Athletics prior to the use of the medication
WADA Notice: BPC-157 is on the WADA Prohibited List (category S0 non-approved substances)
Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models
107.Ryaby JT, Sheller MR, Levine BP, Bramlet DG, Ladd AL, Carney DH
